Check out your Company Bowl for anonymous work chats.
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference. - 2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies - Expected 2026 oncology milestones include seven late-stage data readouts and to have 15 Phase 3 clinical trials ongoing by year end - Additional late-stage trial readouts through 2030+ set to create multiple launch opportunities across tumor types, building BioNTech into a multi-product oncology company - Financial strength with €17.2 billion in cash and cash equivalents plus security investments1, COVID-19 vaccine revenue stream, disciplined R&D spend, and strategic partnerships will continue to enable sustainable innovation - Presentation and webcast at the 44th Annual J.P. Morgan Healthcare Conference from 2:15 – 2:55 pm PT / 11:15 – 11:55 pm CET on Tuesday, January 13, 2026.
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy - Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing - Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% to CureVac’s three-month volume weighted average price of approx. $3.53 as of June 11, 2025 - All-stock acquisition has potential to create long-term value for both companies’ shareholders given their complementary capabilities, focus on mRNA innovation, and shared vision - Transaction is supported by CureVac’s major shareholder dievini Hopp BioTech holding GmbH & Co. KG and certain of its affiliates and expected to close in 2025
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types. -BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types -The co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners’ expertise, resources and global footprint to accelerate BNT327’s path towards potential regulatory approvals and market launches -BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types MAINZ, Germany, and PRINCETON, USA, June 2, 2025 -- BioNTech SE and Bristol Myers Squibb today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting MAINZ, Germany, May 27, 2025 -- BioNTech SE will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, to be held in Chicago, IL, from May 30 to June 3, 2025. The data highlight continued progress of the Company’s clinical programs consisting of complementary therapeutic modalities, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, including antibody-drug conjugates (“ADCs”). “We believe that the next era of cancer medicine will be defined by the interplay of complementary mechanisms and innovative molecules, unlocking their full potential through synergy. Our data presentations at this year's ASCO Annual Meeting show how we aim to help shape this era,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “We will present clinical progress with two of our therapeutic modalities: our next generation immunomodulators, most notably our investigational anti-PD-L1xVEGF-A antibody BNT327, and for one of our ADC programs, which are an important pillar of our combination strategy. These data underline the potential of our assets to improve outcomes for patients.”
BioNTech Expands Partnership with UK Government to Broaden Regional Research and Development Activities - BioNTech plans to invest up to £1 billion over the next 10 years to broaden its research and development activities for innovative medicines in the United Kingdom (“UK”) -The UK Government will give BioNTech a grant of up to £129 million payable over a period of 10 years to support BioNTech’s research and development activities in the UK, marking one of the largest grants of its kind in UK history for a pharmaceutical company - Grant agreement builds on existing multi-year collaboration with the UK Government aimed at benefiting patients by accelerating clinical trials for personalized mRNA immunotherapies and focuses on establishing two new Research and Development (“R&D”) centers and a UK headquarters in London, accommodating BioNTech’s artificial intelligence (“AI”) hub
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer BioNTech SE announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG’s global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025. In his new role as CFO at BioNTech, Ramón Zapata will ensure the Company’s financial direction continues to align with BioNTech’s strategy to become a multi-product company in the oncology field. In preparation for BioNTech’s oncology product launches, he will be responsible for fostering and further optimizing a strong financial infrastructure and performance in key markets. He will continue to drive sustainable organizational excellence and global execution in financial reporting, accounting, tax and treasury, and purchasing with the aim of furthering cost-effective value generation. “Ramón Zapata is an accomplished leader with deep finance expertise who will be taking over from Jens Holstein at an exciting phase.
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update - Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapies - Multiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech’s pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030 - Completed acquisition of Biotheus securing full control of next-generation immunomodulator candidate BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1 - Successfully launched JN.1- and KP.2-adapted COVID-19 vaccines across different countries and regions and maintained global market leadership - Fourth quarter and full year 2024 revenues of €1.2 billion and €2.8 billion**, respectively - Full year 2024 net loss of €0.7 billion and diluted loss per share of €2.77 ($3.00)1 - Cash and cash equivalents plus security investments of €17.4 billion as of December 31, 20242 - Expects 2025 total revenues between €1.7 billion and €2.2 billion ** All numbers in this press release have been rounded.
BioNTech Completes Acquisition of Biotheus -Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers. -With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies. -Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company’s network. MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The acquisition was announced on November 2024 and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, and other bispecific antibody candidates.
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference -Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches -BioNTech aims to develop BNT327/PM8002 as a next-generation immuno-oncology (“IO”) backbone for the Company’s combination strategy targeting a broad range of indications -Progressing development of BNT327/PM8002 with initiation of global clinical trials with registrational potential in first-line small cell lung cancer (“SCLC”) and non-small cell lung cancer (“NSCLC”) -Advancing BNT327/PM8002 combination strategy with initiation of a second antibody drug conjugate (“ADC”) combination trial; additional ADC-combination trials planned to be initiated in 2025 -Progress in mRNA cancer immunotherapy portfolio with multiple randomized trial read-outs of personalized and off-the-shelf candidates expected in 2025 and 2026
BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung -BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den mRNA-Krebsimmuntherapie-Kandidaten -BioNTech will BNT327/PM8002 als innovativen immunonkologischen („IO“) Schlüsselkandidat für die Kombinationsstrategie des Unternehmens entwickeln, der auf ein breites Spektrum von Krebsindikationen abzielt -Fortschritte in der Entwicklung von BNT327/PM8002 mit dem Beginn der globalen, potenziell zulassungsrelevanten klinischen Studien zur Erstlinientherapie von kleinzelligem Lungenkrebs (small-cell lung cancer, „SCLC“) und nicht-kleinzelligem Lungenkrebs (non-small cell lung cancer, „NSCLC“) erzielt -Vorantreiben der Kombinationsstrategie für BNT327/PM8002 mit dem Start einer zweiten Kombinationsstudie mit einem Antikörper-Wirkstoff-Konjugat (antibody drug conjugate, „ADC”); weitere ADC-Kombinationsstudien sind für 2025 geplant -Fortschritte im mRNA-Krebsimmuntherapieportfolio werden mit Daten-Updates aus mehreren randomisierten Studien sowohl für die personalisierten- als auch die off-the-shelf-Kandidaten in den Jahren 2025 und 2026 erwartet
